CheckMate 459: long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

Autores: Sangro Gómez-Acebo, Bruno Carlos; Park, J.; Finn, R.; Cheng, A. ; Mathurin, P. ; Edeline, J. ; Kudo, M.; Han, K. ; Harding, J. ; Merle, P.; Rosmorduc, O. ; Wyrwicz, L.; Schott, E. ; Choo, S.; Kelley, R. ; Begic, D. ; Chen, G. ; Neely, J. ; Tschaika, M. ; Yau, T.